|Articles|March 13, 2020
UHPLC Analysis of mAbs
Author(s)YMC Europe GmbH
This note using YMC-Triart Bio C4 shows a robust separation at high temperatures for three commercially available mAbs: ofatumumab, palivizumab, and panitumumab.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Related Content
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
